Advancement of Artificial Intelligence in various segments of Pharmaceuticals and Epidemics: A Bright Future Ahead

ABSTRACT

The advancement of Artificial intelligence (AI) is found to have dual appearances as it can create the betterment of society and can threaten employment. AI is the automating process which has led to innovation in various educational methods as well as automated business procedures. Major disease areas that use AI tools include cancer, neurology and cardiology. The emergent idea of adopting AI in the drug development process has shifted from hype to hope. AI chains the decision-making processes for prevailing drugs & expanded treatments for other conditions, as well as accelerates the clinical trials procedure by finding the right patients from a number of data sources. Integrating AI into the healthcare ecosystem allows for a multitude of benefits, including automating tasks and analysing big patient data sets to deliver better healthcare faster, and at a lower cost. Machine learning, deep learning and Artificial Intelligence can be utilised to revolutionise the drug development process. At present, the main concern of the Pharmaceutical industry is drug development programmes because of increased R&D costs and reduced efficiency. In this review, we will discuss the applications and role of AI and the possible ways it can advance the effectiveness of the drug development process.